Astellas Pharma to acquire Iveric Bio (ISEE) for $5.9 billion
- S&P 500, Nasdaq notch biggest weekly losses since March
- S&P 500 could end the year over 10% higher from here - Piper Sandler
- Citi says Meta shares to rally in near term on share gains, upcoming AI event
- Ads are coming to Amazon Prime Video next year; Stock pops
- 'Sell the last rate hike' strategy is in action, stocks could fall further - BofA's Hartnett
Astellas Pharma Inc. and Iveric bio, Inc. (NASDAQ: ISEE) today announced that on
"We are pleased to reach an agreement with Iveric Bio, a company with exceptional expertise in the R&D of innovative therapeutics in the ophthalmology field." said
"This transaction with Astellas, a highly respected pharmaceutical company, demonstrates the significant value that we have built for our stockholders and recognizes the tremendous work by our dedicated team at Iveric Bio," said
1. Strategic Objectives of the Acquisition
Astellas aims to become a cutting-edge, VALUE-driven life science innovator to realize its VISION to be "on the forefront of healthcare change to turn innovative science into VALUE for patients."Through Astellas' R&D strategy, Focus Area Approach, it is working to create innovative drugs for diseases with high unmet medical need by identifying unique combinations of biology and therapeutic modality / technology from multiple perspectives. Currently, Astellas has identified five Primary Focuses, including "Blindness & Regeneration", and is prioritizing investment resources in these areas. As such, this transaction is a key step in building Astellas' product portfolio in this important area.
Iveric Bio focuses on the discovery and development of novel treatments in the field of ophthalmology. The company announced in
ACP, a complement C5 inhibitor, is an investigational drug for GA secondary to AMD and has significant potential to deliver value to a large and underserved patient base. ACP met its primary efficacy endpoint (reduction of the rate of GA progression) with statistical significance across two pivotal clinical trials, (GATHER Clinical Trials) and has received breakthrough therapy designation*1 from the FDA for this indication.
Astellas expects that the acquisition of Iveric Bio will not only contribute to Astellas' FY2025 revenue targets set in its Corporate Strategic Plan 2021, but also, that ACP in conjunction with fezolinetant and PADCEV, is anticipated to be a revenue-generating pillar to help compensate for the decline in sales of XTANDI due to anticipated patent expiration later this decade.
In addition, the acquisition of Iveric Bio will provide a foundation of ophthalmology focused capabilities, including a multi-faceted commercial team, expansive network of experts in the ophthalmology field, established relationships with medical institutions, and the infrastructure and experience to drive our combined ophthalmology business going forward. Furthermore, through acquired capabilities, Astellas will accelerate pre-clinical and clinical development and commercialization activities to positively contribute to the goals of Primary Focus, "Blindness & Regeneration."
Funds for the acquisition consist of newly procured funds from bank loans and issuing of commercial paper totaling approximately
The closing of the proposed Acquisition is subject to approval by Iveric Bio's stockholders and other customary closing conditions, including receipt of required regulatory approvals. The companies expect to complete the Acquisition in the second quarter of Astellas' fiscal year 2023 (third calendar quarter of 2023). A copy of the merger agreement regarding the proposed Acquisition will be filed with the U.S. Securities and Exchange Commission ("SEC") and will be publicly available on the SEC's website at (http://www.sec.gov).
2. Overview of Iveric Bio
IVERIC bio, Inc.
8 Sylvan Way
3 Representative's Title and Name
4 Business Description
R&D of pharmaceuticals
5 Stated Capital
6 Consolidated Stockholders' equity
7 Year of Establishment
8 Number of Shares Outstanding
137,616,082 (as of
9 Major shareholders
Vanguard Group, Inc.： 7.4%
BlackRock, Inc.： 7.1%
Deep Track Capital, LP： 5.7%
10 Relationship between Astellas and Iveric Bio
There is no capital relationship between Astellas
There is no personal relationship between Astellas
There is no business relationship between Astellas and Iveric Bio required to be disclosed.
A Related Party
Iveric Bio is not an affiliated party of Astellas.
11 Iveric Bio's consolidated operating results and consolidated financial position for the past three years(**)
Equity per share (US $)
Loss before taxes
Net Loss per share
Dividend per share
* Includes holdings of its subsidiaries and affiliates; based on information from Iveric Bio's definitive proxy statement filed on
** Excerpt from Iveric Bio's Annual Report on Form 10-K for the fiscal year ended
*** There were no sales since these were before the product launch
3. Number of Iveric Bio shares to be acquired by Astellas, acquisition price, and status of shareholdings before and after the Acquisition
1 Number of Iveric Bio shares held by Astellas before the Acquisition
0 (as of
2 Number of Iveric Bio Shares Outstanding as of
3 Acquisition amount (****)
4 Percentage of Iveric Bio shares to be held after the Acquisition
(Number of voting rights: 100%)
**** Acquisition amount includes the full amount required to purchase all outstanding options and restricted stock units
1 Date of Definitive Agreement
2 Estimated Date of stockholder meeting to be held by Iveric Bio
second quarter of Astellas' fiscal year 2023
(third calendar quarter of 2023)
3 Estimated Date of Closing (*****)
second quarter of Astellas' fiscal year 2023
(third calendar quarter of 2023
***** Subject to applicable regulatory approvals
5. Financial Impact of the Acquisition
The impact of the consummation of the Acquisition on Astellas' financial results is not reflected in Astellas' consolidated financial forecasts for the fiscal year ending
6. Financial and Legal Advisors
J.P. Morgan Securities LLC, acting through its affiliate JPMorgan Securities Japan Co., Ltd., is acting as exclusive financial advisor to Astellas and Jones Day is acting as Astellas' legal counsel. BofA Securities, Inc. and Centerview Partners LLC are serving as Iveric Bio's exclusive financial advisors and Skadden, Arps, Slate, Meagher & Flom LLP is serving as Iveric Bio's legal counsel, with Wilmer Cutler Pickering Hale and Dorr LLP advising on general corporate and licensing matters.
*1: The FDA's breakthrough therapy designation is intended to expedite the development and review of drugs for serious or life-threatening conditions. The criteria for breakthrough therapy designation require preliminary clinical evidence that demonstrates the drug may have substantial improvement on at least one clinically significant endpoint over available therapy. FDA will review the full data submitted to support approval of drugs designated as breakthrough therapies to determine whether the drugs are safe and effective for their intended use before they are approved for marketing.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cisco Systems (CSCO) to Acquire Splunk (SPLK) for $157 Per Share, $28 Billion
- 3D Systems (DDD) Supports Leading Proxy Advisor ISS’ Recommendation AGAINST Stratasys’ (SSYS) Planned All-Stock Merger with Desktop Metal (DM)
- Conduit Pharmaceuticals and Murphy Canyon Acquisition (MURF) Complete Merger
Create E-mail Alert Related CategoriesCorporate News, Hot Corp. News, Hot M&A, Mergers and Acquisitions
Related EntitiesJPMorgan, Dividend, Vanguard, Earnings, Definitive Agreement, PDUFA, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!